Alemtuzumab treatment in Denmark

Asta Theodorsdottir prsent data from the The Danish Multiple Sclerosis Registry about the demographics of the alemtuzumab-treated population in Denmark; the treatment strategy; the number of cycles and its relation to previous disease modifying treatments (DMTs); and the frequency of switch to other DMTs.

In this MEDtalk Tone Berge present new insights into immune-cell processes in MS through evaluate dysregulation af CD4+ and CD8+ cells from MS patients.

Smoking, air pollution and MS

Hear the latest data on the association between smoking and an increased risk of MS. There are several interesting new data.

Adverse events with fatal outcome

Sporadic cases of fatal adverse events have been reported during treatment of multiple sclerosis with alemtuzumab. In this MEDtalk Trygve Holmøy present a study based on European Medicines Agency database of suspected adverse reactions related to medicinal products in the European Economic Area (EudraVigilance), for fatal adverse events associated with treatment with alemtuzumab. Trygve Holmøy and colleagues identified nine cases with a probable and one case with a possible causal relationship between alemtuzumab treatment and a fatal adverse event.

Highlights from ECTRIMS

Melinda Magyari, Head of the Danish MS Registry, gives in this MEdtalk some of her highlights from the ECTRIMS Congress.

Patients with MS are often initially treated with moderately effective disease modifying therapies, and in case of insufficient treatment response therapy is escalated to high efficacy disease modifying therapies. In this MEDtalk Mathias Due Buron present Danish data for difference of disease activity in patients started initially on high efficacy disease modifying therapies compared to similar patients started moderately effective disease modifying therapies.